ChromaDex Corporation (CDXC) News
Filter CDXC News Items
CDXC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CDXC News Highlights
- CDXC's 30 day story count now stands at 2.
- Over the past 8 days, the trend for CDXC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest CDXC News From Around the Web
Below are the latest news stories about CHROMADEX CORP that investors may wish to consider to help them evaluate CDXC as an investment opportunity.
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®LOS ANGELES, December 20, 2023--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, is proud to announce its inaugural initiative to support the US Military. |
Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+Neurohacker Collective, an acclaimed American science team that has been formulating advanced nutritional supplements since 2015, has just created an NAD+ supplement called Qualia NAD+ that tackles the challenge of boosting NAD+ levels in aging Americans.* |
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)LOS ANGELES, November 30, 2023--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson’s disease (PD). This study was part of the ChromaDex External Research Program (CERP™), which donated ChromaDex’s patented NR ingredient, Niagen®, the most efficient and high quality NAD+ precur |
An Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 44% UndervaluedKey Insights The projected fair value for ChromaDex is US$2.57 based on 2 Stage Free Cash Flow to Equity ChromaDex is... |
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) PatientsLOS ANGELES, November 15, 2023--ChromaDex Corp. (NASDAQ:CDXC), one of the global authorities on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, shares results from a phase II clinical study published in the peer-reviewed journal, Movement Disorders, by a team of researchers led by Dr. Hilde Nilsen, University of Oslo, Arkershus University Hospital, Norway. The clinical trial was part of the ChromaDex External Research Program (CERP™), which donated ChromaDex’s patented nicot |
ChromaDex Corporation (NASDAQ:CDXC) Q3 2023 Earnings Call TranscriptChromaDex Corporation (NASDAQ:CDXC) Q3 2023 Earnings Call Transcript November 8, 2023 ChromaDex Corporation beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.03. Operator: Hello and thank you for standing by. My name is Regina and I’ll be your conference operator today. At this time, I’d like to welcome everyone to the ChromaDex Corporation Third […] |
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023LOS ANGELES, November 09, 2023--ChromaDex Corporation (NASDAQ: CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, November 14, 2023, at 2:00 PM EDT. ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend these live events. |
ChromaDex Corp (CDXC) Reports Growth in Net Sales and Positive Adjusted EBITDA in Q3 2023Financial Discipline and Operational Efficiency Drive Improved Results |
ChromaDex Corporation Reports Third Quarter 2023 Financial ResultsLOS ANGELES, November 08, 2023--ChromaDex Corp. (NASDAQ: CDXC) today announced financial results for the third quarter of 2023. |
ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers NationwideLOS ANGELES, November 01, 2023--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, launches its clinical strength Tru Niagen® Pro 1,000mg, featuring 1,000mg of Niagen® (patented Nicotinamide Riboside or NR), one of the most efficient and superior quality NAD+ precursors on the market, to consumers nationwide. With 1,000mg of Niagen used in over 50% of published clinical studies, this serving is redefining research for NAD+ re |